Abstract
PurposeTo determine the clinical outcomes of brand-to- generic oxcarbazepine (OXC) switch in patients with epilepsy. MethodsThis prospective observational study included 103 patients treated with OXC in the tertiary outpatient epilepsy clinic. In 2016 the price of the brand-name OXC in Poland increased by 10 times in comparison to the generic products. Assuming that the majority of the patients would be forced to switch to generic drugs due to financial issues we decided to follow them prospectively to evaluate the safety of switching from brand-name to generic OXC. ResultsA quarter of our cohort (26%) decided to continue on brand-name OXC, the majority (74%) switched to generic products. We did not find differences in terms of frequency of seizures and adverse events between patients continuing on brand-name OXC and those switching to generic AED. ConclusionThe switching from brand-name to generic OXC seems to be safe, however, larger prospective studies are required in order to confirm our findings.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
